Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments

[0044]The present invention will now be described more specifically with reference to the following Embodiments. It is to be noted that the following descriptions of preferred Embodiments of this invention are presented herein for purpose of illustration and description only; it is not intended to be exhaustive or to be limited to the precise form disclosed.

[0045]As illustrated above, xanthine-based compound is nominated as 7-[244-(2-chlorophenyl)piperazinyl]ethyl]-1,3-dimethylxanthine which has a structural formula (Formula I) as follows.

[0046]Among these, 2-chlorophenyl piperazine group is the aforementioned o-CPP, which regulates serotonergic neurotransmission and NO / cGMP pathway. In addition, xanthine-based compound does not generate lethargy effect per se since o-CPP lacks anti-histaminergic activity.

[0047]When animals are stimulated (such as psychological stress) or has abnormal physiological conditions to influence the original serotonergic neurotransmission, they might induce